4.6 Article

Anti-chromatin (anti-nucleosome) antibodies: Diagnostic and clinical value

期刊

AUTOIMMUNITY REVIEWS
卷 7, 期 8, 页码 606-611

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.autrev.2008.06.005

关键词

Anti-chromatin antibodies; Anti-nucleosome antibodies; Systemic lupus erythematosus

向作者/读者索取更多资源

Anti-chromatin (nucleosome) autoantibodies were one of the first autoantibodies ever detected since they make up the majority of antibodies causing LE Cell formation. The prevalence of anti-chromatin antibodies in systemic lupus erythematosus (SLE) varies from 50% to 100%, being similar to that of the classical positive LE cell. The presence of these antibodies can be used, in conjunction with clinical findings and other laboratory tests, to help in the diagnosis of SLE and drug-induced lupus. Anti-chromatin antibodies have also been found in a lesser percentage of other autoimmune disorders such as primary Sjogren's syndrome and primary antiphospholipid syndrome. The presence of anti-chromatin antibodies has also been linked to glomerulonephritis and disease activity in SLE patients. Recent studies demonstrated the induction of anti-chromatin (anti-nucleosome) antibodies after an anti-tumour necrosis factor (TNF)-alpha agent treatment. (C) 2008 Elsevier B.V. All rights reserved

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, General & Internal

High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study

Beatriz Frade-Sosa, Andres Ponce, Virginia Ruiz-Esquide, Maria Jesus Garcia-Yebenes, Rosa Morla, Nuria Sapena, Julio Ramirez, Ana Belen Azuaga, Juan Camilo Sarmiento, Juan D. Canete, Jose A. Gomez-Puerta, Raimon Sanmarti

Summary: The study aimed to investigate whether hsCRP reflects the inflammatory disease state in RA patients receiving different types of medications. The results showed that hsCRP is not associated with inflammatory disease status in patients receiving anti-IL-6R treatment, but is associated with US synovitis in patients receiving JAKi treatment.

DIAGNOSTICS (2022)

Editorial Material Medicine, General & Internal

Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines

Gema M. Lledo, Marc Xipell, Adriana Garcia-Herrera, Laura Bueno, Ricard Cervera, Maria Galindo, Jose A. Gomez-Puerta, Enrique Morales, Manuel Praga, Jorge E. Rojas, Guillermo Ruiz-Irastorza, Olga Sanchez Pernaute, David Jayne, Gerard Espinosa, Luis F. Quintana

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2022)

Article Rheumatology

Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry

Richard Conway, Elena Nikiphorou, Christiana A. Demetriou, Candice Low, Kelly Leamy, John G. Ryan, Ronan Kavanagh, Alexander D. Fraser, John J. Carey, Paul O'Connell, Rachael M. Flood, Ronan H. Mullan, David J. Kane, Nicola Ambrose, Frances Stafford, Philip C. Robinson, Jean W. Liew, Rebecca Grainger, Geraldine M. McCarthy

Summary: This study used data from the COVID-19 Global Rheumatology Alliance to describe COVID-19 outcomes for people with rheumatic disease in Ireland. The results showed that there was no temporal trend in COVID-19-related hospitalization and mortality outcomes for these patients.

RHEUMATOLOGY (2022)

Article Medicine, Research & Experimental

The synovial and blood monocyte DNA methylomes mirror prognosis, evolution, and treatment in early arthritis

Carlos de la Calle-Fabregat, Javier Rodriguez-Ubreva, Laura Ciudad, Julio Ramirez, Raquel Celis, Ana Belen Azuaga, Andrea Cuervo, Eduard Graell, Carolina Perez-Garcia, Cesar Diaz-Torne, Georgina Salvador, Jose A. Gomez-Puerta, Isabel Haro, Raimon Sanmarti, Juan D. Canete, Esteban Ballestar

Summary: Identifying predictive biomarkers at early stages of inflammatory arthritis is crucial for appropriate therapies. This study investigated the association between DNA methylation in blood and synovial fluid MOs and clinical features in patients with early inflammatory arthritis. The results suggest that DNA methylation can be used as biomarkers for disease activity and treatment efficacy.

JCI INSIGHT (2022)

Article Medicine, General & Internal

Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study

Jose A. Gomez-Puerta, David Lobo-Prat, Carolina Perez-Garcia, Andres Ponce, Beatriz Frade-sosa, Ana Milena Millan Arciniegas, Fabiola Ojeda, Virginia Ruiz-Esquide, Hector Corominas

Summary: The study described different clinical patterns of rheumatic irAEs induced by ICI, classified based on treatment and irAEs. Patients receiving combined ICI therapy showed earlier onset of symptoms. Patients presenting as RA-like had a higher risk of persistent arthritis.

FRONTIERS IN MEDICINE (2022)

Article Medicine, General & Internal

Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis

Andres Ponce, Beatriz Frade-Sosa, Juan C. Sarmiento-Monroy, Nuria Sapena, Julio Ramirez, Ana Belen Azuaga, Rosa Morla, Virginia Ruiz-Esquide, Juan D. Canete, Raimon Sanmarti, Jose A. Gomez-Puerta

Summary: ICI-induced arthritis presents inflammatory patterns on imaging studies similar to conventional inflammatory arthropathies, and ultrasound and MRI play important roles in the diagnosis of these syndromes.

DIAGNOSTICS (2022)

Article Rheumatology

Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

Zara Izadi, Milena A. Gianfrancesco, Gabriela Schmajuk, Lindsay Jacobsohn, Patricia Katz, Stephanie Rush, Clairissa Ja, Tiffany Taylor, Kie Shidara, Maria Danila, Katherine D. Wysham, Anja Strangfeld, Elsa F. Mateus, Kimme L. Hyrich, Laure Gossec, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schaefer, Samar Al-Emadi, Jeffrey A. Sparks, Tiffany Y-T Hsu, Naomi J. Patel, Leanna Wise, Emily Gilbert, Ali Duarte-Garcia, Maria O. Valenzuela-Almada, Manuel F. Ugarte-Gil, Lotta Ljung, Carlo A. Scire, Greta Carrara, Eric Hachulla, Christophe Richez, Patrice Cacoub, Thierry Thomas, Maria J. Santos, Miguel Bernardes, Rebecca Hasseli, Anne Regierer, Hendrik Schulze-Koops, Ulf Mueller-Ladner, Guillermo Pons-Estel, Romina Tanten, Romina E. Nieto, Cecilia N. Pisoni, Yohana S. Tissera, Ricardo Xavier, Claudia D. Lopes Marques, Gecilmara C. S. Pileggi, Philip C. Robinson, Pedro M. Machado, Emily Sirotich, Jean W. Liew, Jonathan S. Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Monique Gore-Massy, Zachary S. Wallace, Jinoos Yazdany

Summary: This study investigated the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease. The findings suggest that air pollution, proportion of the population aged 65 years or older, and population mobility are independently associated with higher odds of mortality. Factors such as number of hospital beds, human development index, government response stringency, and follow-up time are independently associated with lower odds of mortality.

LANCET RHEUMATOLOGY (2022)

Article Rheumatology

Controversies in the Management of Antiphospholipid Syndrome

Sabrina V. Porta, Danieli Castro Oliveira de Andrade, Doruk Erkan, Jose A. Gomez-Puerta, Luis J. Jara, Paula Alba Moreyra, Guillermo J. Pons-Estel

Summary: Strategies to prevent thrombosis in aPL-positive patients are crucial, and the risk varies depending on additional factors. Recurrent thrombosis is common despite treatment, and the effectiveness of new oral anticoagulants and low-dose aspirin is debated. There is an urgent need to identify patients who may benefit from aspirin use. This article provides a useful discussion to aid treatment decision-making in clinical practice.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2023)

Article Oncology

Calprotectin in Patients with Rheumatic Immunomediated Adverse Effects Induced by Checkpoints Inhibitors

Beatriz Frade-Sosa, Chafik Alejandro Chacur, Josep M. Auge, Andres Ponce, Juan C. Sarmiento-Monroy, Ana Belen Azuaga, Nuria Sapena, Julio Ramirez, Virginia Ruiz-Esquide, Rosa Morla, Sandra Farietta, Patricia Corzo, Juan D. Canete, Raimon Sanmarti, Jose A. Gomez-Puerta

Summary: This study aimed to evaluate the serum levels of calprotectin in patients with rheumatic immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) treatment. The results showed that calprotectin can serve as a marker of inflammatory activity in patients with rheumatic irAEs.

CANCERS (2023)

Article Immunology

From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies

Marc Xipell, Gema M. Lledo, Allyson C. Egan, Farah Tamirou, Cristina Serrano del Castillo, Jordi Rovira, Jose A. Gomez-Puerta, Adriana Garcia-Herrera, Ricard Cervera, Andreas Kronbichler, David R. W. Jayne, Hans-Joachim Anders, Frederic Houssiau, Gerard Espinosa, Luis F. Quintana

Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by loss of tolerance against nuclear and cytoplasmic self-antigens, induction of immunity, and tissue inflammation. Lupus nephritis (LN) is a common complication of SLE, affecting around 30% of patients at disease onset and up to 50-60% within the first 10 years. This review focuses on the pathogenic mechanisms of SLE, the immunological pathways of kidney damage in LN, and the rationale for the treatment of LN.

AUTOIMMUNITY REVIEWS (2023)

Article Rheumatology

2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

Medha Barbhaiya, Stephane Zuily, Ray Naden, Alison Hendry, Florian Manneville, Mary-Carmen Amigo, Zahir Amoura, Danieli Andrade, Laura Andreoli, Bahar Artim-Esen, Tatsuya Atsumi, Tadej Avcin, Michael H. Belmont, Maria Laura Bertolaccini, D. Ware Branch, Graziela Carvalheiras, Alessandro Casini, Ricard Cervera, Hannah Cohen, Nathalie Costedoat-Chalumeau, Mark Crowther, Guilherme de Jesus, Aurelien Delluc, Sheetal Desai, Maria De Sancho, Katrien M. Devreese, Reyhan Diz-Kucukkaya, Ali Duarte-Garcia, Camille Frances, David Garcia, Jean-Christophe Gris, Natasha Jordan, Rebecca K. Leaf, Nina Kello, Jason S. Knight, Carl Laskin, Alfred Lee, Kimberly Legault, Steve R. Levine, Roger A. Levy, Maarten Limper, Michael D. Lockshin, Karoline Mayer-Pickel, Jack Musial, Pier Luigi Meroni, Giovanni Orsolini, Thomas L. Ortel, Vittorio Pengo, Michelle Petri, Guillermo Pons-Estel, Jose A. Gomez-Puerta, Quentin Raimboug, Robert Roubey, Giovanni Sanna, Surya V. Seshan, Savino Sciascia, Maria G. Tektonidou, Angela Tincani, Denis Wahl, Rohan Willis, Cecile Yelnik, Catherine Zuily, Francis Guillemin, Karen Costenbader, Doruk Erkan

Summary: A new set of classification criteria for antiphospholipid syndrome (APS) has been developed with high specificity. Supported by the American College of Rheumatology (ACR) and EULAR, this study utilized rigorous methodology and involved multidisciplinary international input.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression

Lorena Rodriguez-Martinez, Cristina Garcia-Moreno, Eva Perez-Pampin, Maria J. Gomara, Juan C. Sarmiento-Monroy, Yolanda Lopez-Golan, Jose A. Gomez-Puerta, Antonio Mera-Varela, Carmen Conde, Raimon Sanmarti, Isabel Haro, Antonio Gonzalez

Summary: Autoantibodies play a critical role in the pathogenesis and clinical assessment of rheumatoid arthritis. The anti-malondialdehyde-acetaldehyde (anti-MAA) antibodies have been claimed to have high sensitivity for all rheumatoid arthritis patients. However, the sensitivity of anti-MAA antibodies varies significantly between patient collections and is determined by complex factors including ethnicity, smoking, and sex.

ARTHRITIS RESEARCH & THERAPY (2023)

Review Rheumatology

Complete disappearance of pulmonary rheumatoid nodules after long term rituximab treatment: case report

Beatriz Frade-Sosa, Ana Belen Azuaga, Virginia Ruiz-Esquide, Jose A. Gomez-Puerta, Raimon Sanmarti

Summary: This study reported a case of a patient with rheumatoid arthritis who had pulmonary rheumatoid nodules diagnosed while receiving etanercept and experienced complete resolution of the nodules after 5 years of rituximab treatment.

RHEUMATOLOGY INTERNATIONAL (2022)

Article Rheumatology

Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors

Beatriz Frade-Sosa, Andres Ponce, Jose Inciarte-Mundo, Rosa Morla, Viginia Ruiz-Esquide, Laura Macias, Ana Belen Azuaga, Julio Ramirez, Juan D. Canete, Jordi Yague, Josep M. Auge, Jose A. Gomez-Puerta, Raimon Sanmarti

Summary: The study found that plasma calprotectin may be a sensitive biomarker of synovial inflammation in RA patients treated with anti-rIL-6 or JAKi.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2022)

Article Rheumatology

Proliferative synovitis, an ultrasound pattern associated with ACPA-positive patients and erosive disease in rheumatoid arthritis

J. Ramirez, A. B. Azuaga-Pinango, B. Frade-Sosa, R. Gumucio-Sanguino, K. Cajiao-Sanchez, A. M. Cuervo, R. Celis, J. A. Narvaez, V Ruiz-Esquide, R. Castellanos-Moreira, A. Ponce, J. A. Gomez-Puerta, J. L. Pablos, R. Sanmarti, J. D. Canete

Summary: In patients with rheumatoid arthritis (RA), ultrasound proliferative synovitis (US PS) is associated with ACPA positivity, erosive disease, and a greater likelihood of needing to change disease-modifying anti-rheumatic drug therapy in the long-term. At the synovial level, this ultrasound pattern is characterized by higher vessel density.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2022)

暂无数据